对HER2-低表达性乳腺癌全球研究的图书统计分析
Junpeng Zhu1, Jin Hu2, Hao Lei3
1Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Discover oncology
|November 19, 2025
概括
人类表皮生长因子受体2 (HER2) -低乳腺癌的研究正在迅速扩大. 本文献分析揭示了全球主要研究趋势,重点关注预后因素,诊断和向治疗,以改善患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 生物医学研究生物医学研究
背景情况:
- 异常的人体表皮生长因子受体2 (HER2) 表达与乳腺癌预后有关.
- 自2018年以来,对HER2-低乳腺癌的研究显著增加.
研究的目的:
- 评估 HER2 低乳腺癌相关文献的全球分布.
- 确定当前的研究重点和该领域的新兴趋势.
主要方法:
- 从2018年1月到2025年3月,通过Web of Science对573篇文章进行了图书统计分析.
- 使用了Bibliometrix,VOSviewer和CiteSpace来系统地检查研究成果.
主要成果:
- 文学来自54个国家,其中中国和美国是主要贡献者.
- 关键的研究领域包括预后因素,免疫组织化学,向治疗,诊断和生存结果.
- 在先前治疗的HER2-低高级乳腺癌中,trastuzumab Deruxtecan是最常被引用的参考.
结论:
- 图书统计分析表明,HER2-低乳腺癌研究的显著上升趋势.
- 该研究强调了临床意义,并确定了这一关键领域的研究重点和热点.
相关概念视频
Cancer Survival Analysis
633
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
633
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


